About this document

Ijms 20 04504 by bushbao1999 is a document available to read on EtoBox.

The review discusses chemoresistance in pancreatic cancer, particularly focusing on pancreatic ductal adenocarcinoma (PDAC), which is a leading cause of cancer-related deaths. Despite advancements in treatment options like gemcitabine and FOLFIRINOX, the development of chemoresistance significantly hampers treatment efficacy. The authors suggest that understanding the mechanisms behind chemoresistance may enhance the effectiveness of existing therapies and lead to improved outcomes for patients.

Author

bushbao1999

Language

EN